U.S. stock futures were higher this morning, with the Dow futures gaining more than 150 points on Monday.
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) fell sharply in today’s pre-market trading after the company suspended ELEVIDYS shipments and paused ENVISION trial after second fatal liver failure in non-ambulatory Duchenne patients.
Sarepta Therapeutics shares tumbled 31.4% to $24.86 in the pre-market trading session.
Here are some other stocks moving lower in …
Full story available on Benzinga.com
U.S. stock futures were higher this morning, with the Dow futures gaining more than 150 points on Monday.
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) fell sharply in today’s pre-market trading after the company suspended ELEVIDYS shipments and paused ENVISION trial after second fatal liver failure in non-ambulatory Duchenne patients.
Sarepta Therapeutics shares tumbled 31.4% to $24.86 in the pre-market trading session.
Here are some other stocks moving lower in …
Full story available on Benzinga.com
U.S. stock futures were higher this morning, with the Dow futures gaining more than 150 points on Monday.
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) fell sharply in today’s pre-market trading after the company suspended ELEVIDYS shipments and paused ENVISION trial after second fatal liver failure in non-ambulatory Duchenne patients.
Sarepta Therapeutics shares tumbled 31.4% to $24.86 in the pre-market trading session.
Here are some other stocks moving lower in …Full story available on Benzinga.com Read Morebig losers, GROY, IONQ, KULR, News, OMDA, Premarket Movers, RGEN, SLDB, SRPT, TNGX, Pre-Market Outlook, Markets, Movers, Trading Ideas, RGEN, US7599161095, SRPT, SLDB, KULR, IONQ, GROY, TNGX, OMDA, News, Pre-Market Outlook, Markets, Movers, Trading Ideas, Benzinga Markets
